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PURPOSE. While the association between the gut microbiome and the immune system
has been studied in autoimmune disorders, little is known about ocular disease. Previ-
ously we reported that IRT5, a mixture of five probiotic strains, could suppress autoim-
mune dry eye. In this study, we investigated the mechanism by which IRT5 performs its
immunomodulatory function in a mouse model of autoimmune dry eye.
METHODS. NOD.B10.H2b mice were used as an autoimmune dry eye model. Either IRT5
or PBS was gavaged orally for 3 weeks, with or without 5 days of antibiotic pretreatment.
The effects on clinical features, extraorbital lacrimal gland and spleen proteins, and fecal
microbiota were analyzed.
RESULTS. The ocular staining score was lower, and tear secretion was higher, in the
IRT5-treated groups than in the PBS-treated groups. After IRT5 treatment, the down-
regulated lacrimal gland proteins were enriched in the biological processes of defense
response and immune system process. The relative abundances of 33 operational taxo-
nomic units were higher, and 53 were lower, in the feces of the IRT5-treated groups than
in those of the PBS-treated groups. IRT5 administration without antibiotic pretreatment
also showed immunomodulatory functions with increases in the Lactobacillus helveti-
cus group and Lactobacillus hamsteri. Additional proteomic assays revealed a decrease
of proteins related to antigen-presenting processes in the CD11b+ and CD11c+ cells of
spleen in the IRT5-treated groups.
CONCLUSIONS. Changes in the gut microbiome after IRT5 treatment improved clinical mani-
festations in the autoimmune dry eye model via the downregulation of antigen-presenting
processes in immune networks.
Keywords: IRT5, probiotics, autoimmune dry eye, gut microbiome, proteomics, antigen
presentation, cornea
The human microbiome project and advancement inmetagenomic analysis have revealed that the gut
microbiome modulates human diseases by affecting the
metabolism and both innate and adaptive immunity.1–5 Dry
eye disease associated with Sjögren syndrome is a well-
known autoimmune disease.6 Many autoimmune disease
or metabolic syndromes, including Sjögren syndrome, may
be affected by aberrant interaction between the immune
system and gut microbiome.3–5,7,8 For example, a dysbiotic
intestinal microbiome has been shown to affect autoimmune
uveitis and dry eye.8–13
Whether probiotics exert beneficial effects on inflam-
matory or metabolic diseases has long been debated.14,15
Recent meta-analytic human studies reported favorable
microbiome effects on clinical manifestations in diabetes,
necrotizing enterocolitis, inflammatory bowel disease, and
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eczema but not in rheumatoid arthritis.16–20 There has also
been a clinical trial reporting that administration of Bifi-
dobacterium mixture may attenuate dry eye syndrome.21
IRT5 is a probiotic mixture of five strains that includes
Bifidobacterium bifidum, Lactobacillus acidophilus, Lacto-
bacillus casei, Lactobacillus reuteri, and Streptococcus ther-
mophilus.22 IRT5 exerts an anti-inflammatory effect in exper-
imental autoimmune models of myasthenia gravis, colitis,
and encephalomyelitis.22–24 Previously, we demonstrated the
beneficial effect of IRT5 on the clinical manifestations of
autoimmune uveitis and dry eye models but not on those
of a corneal allotransplantation model.25
Although IRT5, especially B. bifidum, has been stud-
ied for its anti-inflammatory effects, the precise mecha-
nism by which IRT5 improves dry eye is not known.26,27
A recent human study reported protein changes in the
lacrimal and tear fluid of patients with dry eye.28 There-
fore, to understand the pathophysiologic changes of the
lacrimal gland and its role as a possible target organ during
crosstalk between the gut microbiome and the immune
system, we investigated the mechanism by which IRT5
probiotics alter the gut microbiota and the proteome of the




Twelve-week-old male NOD.B10.H2b mice (from The
Jackson Laboratory, Bar Harbor, ME, USA) were used as
the autoimmune dry eye model (n = 35). Due to the poor
breeding properties of NOD.B10.H2b mice, we conducted
four repeated experiments focused on different analy-
sis. The number of mice used in each experiment is as
follows.
• Experiment 1: Five mice in the PBS group and five
mice in the IRT5 group were used for the clinical
evaluation and proteomic analysis of the extraorbital
lacrimal glands after antibiotic pretreatment.
• Experiment 2: Four mice in the PBS group and
five mice in the IRT5 group were used for the clini-
cal evaluation and proteomic analysis of the lymph
nodes and spleen after antibiotic pretreatment.
• Experiment 3: Three mice in the PBS group and four
mice in the IRT5 group were used for clinical eval-
uation and gut microbiome analysis after antibiotic
pretreatment.
• Experiment 4: Four mice in the PBS group and five
mice in the IRT5 group were used for clinical evalu-
ation and gut microbiome analysis without antibiotic
pretreatment.
Mice were bred in a specific pathogen-free facility at the
Biomedical Research Institute of Seoul National University
Hospital (Seoul, Korea) and maintained at 22–24°C, relative
humidity 55% ± 5%, with free access to food and water. All
mice were managed in accordance with the Association for
Research in Vision and Ophthalmology guidelines for the
Use of Animals in Ophthalmic and Vision Research. The
study was approved by the Institutional Animal Care and
Use Committee of the Seoul National University Biomedical
Research Institute (IAUCUC No. 17-0093-C1A0 and 18-0129-
S1A0).
Antibiotics Pretreatment and IRT5 Treatment
Of the 35 mice, antibiotic pretreatment was performed on
26 and the remaining 9 were not pretreated.
In the pretreatment group, a cocktail of 1 g l−1 ampi-
cillin, 500 mg l−1 vancomycin, and 1 g l−1 metronidazole
(all from Sigma-Aldrich, St. Louis, MO, USA) was adminis-
tered in drinking water for 5 days before the start of the
treatment. The IRT5 probiotic powder containing 2 × 108
CFU g−1 of five strains (L. casei, L. acidophilus, L. reuteri,
B. bifidum, and S. thermophilus) was kindly provided by
Young-Tae Ahn (Korea Yakult Co., Giheung, Korea). Either
PBS alone (n = 12) or 1 × 109 IRT5 probiotics (n = 14) in
300 μL PBS was gavaged orally once a day for 3 weeks.
In the non-pretreatment group, either PBS (n = 4) or
IRT5 probiotics (n = 5) was gavaged orally once a day for
3 weeks.
Clinical Evaluation
Phenol red–impregnated cotton threads (FCI Ophthalmics,
Pembroke, MA, USA) were inserted for 60 seconds into the
lateral canthus of mice under anesthesia (anesthetized using
a mixture of zoletil and xylazine at a ratio of 1:3). The
amount of tear secreted was determined by measuring the
wet length of the wet thread in millimeters. After instilling
one drop of 3% Lissamine Green B (Sigma-Aldrich) to the
lower lateral conjunctival sac, corneal epithelial defect was
scored in a blinded manner as follows: 0 if no punctuate
staining was observed, 1 if less than one-third of the cornea
was staining, 2 if two-thirds or less was stained, and 3 if
more than two-thirds of the cornea was stained.25,29
Proteomics Sample Preparation
Lacrimal gland samples from NOD mice treated with PBS
(control, n = 5) or IRT5 (n = 5) after antibiotic pretreatment
were individually pulverized using a Cryoprep device (CP02;
Covaris, Inc., Woburn, MA, USA). The pulverized tissue
powder was sonicated in lysis buffer (4% SDS, 0.1M Tris-
HCl pH 7.6, 1× Halt protease inhibitor cocktail [Hoffmann-
La Roche AG, Basel, Switzerland] in 10 mL). The homogenate
was centrifuged at 16,000 × g and 20°C for 10 minutes,
and the supernatant was collected for protein digestion. The
protein concentration was measured using a bicinchoninic
acid (BCA) protein assay (BCA Protein Assay Kit; Thermo
Fisher Scientific, San Jose, CA, USA). One hundred micro-
grams of proteins from each tissue was digested using a
filter-aided sample preparation (FASP) method following
published instructions.30 The peptides were labeled with
TMT 10-plex reagent (Thermo Fisher, Waltham, MA, USA),
according to the manufacturer’s protocol. The five peptide
samples from the PBS-treated mice were labeled as 126,
127N, 127C, 128N, and 128C, and the five from the IRT5
mice were labeled as 129N, 129C, 130N, 130C, and 131.
The labeled peptides were pooled and fractionated into 12
fractions using high-pH reversed-phase fractionation. The
peptides from the 12 fractions were dried and desalted using
a C18 spin column (Thermo Fisher).
The spleens of the NOD mice treated with PBS
(control, n = 4) or IRT5 (n = 5) after antibiotics pretreat-
ment were cut in half. The CD11b+ cells were sorted in
one half and the CD11c+ cells were sorted in the other
half. The cervical and mesenteric lymph nodes of each
mouse were pooled and only CD3+ cells were obtained.
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After cell sorting, the cells from each mouse were pooled
and proteomic sample preparation was carried out. The cells
were lysed using the same lysis buffer mentioned above
and centrifuged for 10 minutes at 16,000 × g in order to
acquire the protein supernatant. The protein concentration
of each cell was measured using BCA and 50 μg protein
was digested using FASP digestion. The digested peptides
were labeled with TMT 6-plex reagent (Thermo Fisher) and
pooled into one sample (126: IRT5 lymph node CD3+, 127:
IRT5 spleen CD11b+, 128: IRT5 spleen CD11c+, 129: PBS
lymph node CD3+, 130: PBS spleen CD11b+, and 131: PBS
spleen CD11c+). The pooled sample was fractionated into
12 fractions and each fraction was desalted and analyzed
using liquid chromatography–mass spectrometry (LC-MS)
analysis.
LC-MS/MS Analysis
The desalted peptides were resuspended in 0.1% formic acid
in water and injected into a Q Exactive orbitrap hybrid mass
spectrometer (Thermo Fisher) coupled with an Easy-nLC
1000. The peptides (1 μg) were loaded onto a trap column
(2 cm × 75 μm i.d. packed with 2 μm C18) and an analytical
column (70 cm × 75 μm i.d. packed with 3 μm C18). A 180-
minute gradient with a flow rate of 0.45 μL/min separated
the peptides depending on linear acetonitrile (ACN) gradi-
ent (changing from 5% to 40% solvent B in 150 minutes from
40% to 80% solvent B in 5 minutes, holding at 80% solvent
B for 10 minutes, and equilibrating the column with 5%
solvent B for 15 minutes). A data-dependent scan was used,
and the top 12 peaks were selected and isolated for frag-
mentation. The resolution of the complete MS was 70,000
and that of the MS/MS was 17,500 for the TMT 6-plex and
35,000 to distinguish TMT 10-plex mass. Precursor ions were
fragmented using a normalized collision energy of 30. The
dynamic exclusion was set to 30 seconds.
Proteomics Data Analysis
Raw data from the MS were processed using postexper-
iment monoisotopic mass refinement to increase sensitiv-
ity in peptide identification by selecting unique mass class.
Refined data were analyzed using Proteome Discoverer 2.2
(Thermo Fisher). Seqeust HT and the Uniprot mouse refer-
ence were used (released in August 2018). For strict peptide
identification, 0.01 false discovery rate (FDR) was applied as
the peptide level. In addition, more than one unique peptide
was always used to identify a protein. To quantify the protein
ratio, only proteins that had more than two unique peptides
were selected and quantified using reporter ion intensities.
As the sum of the ion intensities of the reporter ions from
each plex should be identical, all the peptide intensities
were normalized to the total reporter ion intensity. Gene
ontology analysis of differentially expressed proteins (DEPs)
was performed to understand the biological functions of
the DEPs in the mouse model. Biological process, cellular
components, molecular function, and the Kyoto Encyclope-
dia of Genes and Genomes (KEGG) pathway were validated
using DAVID bioinformatics resources. A cutoff of ≤0.05 was
applied, and the STRING database was used for interpret-
ing protein interactions. Expression changes were weighed
based on degree and betweenness centrality, which reflects
the amount of control that a node exerts over the interac-
tions of other nodes in the network.
Fecal Microbiota 16S Ribosomal RNA Analysis
Fecal pellets were collected directly from the anus
of each mouse by holding the mouse in one hand
while allowing it to defecate into a sterile tube. The
collected feces were immediately stored at –80°C. For
the analysis of bacteria in the feces, PCR amplification
was performed using extracted DNA and the bacterial
PCR primers 341F (5′-TCGTCGGCAGCGTC-AGATGTGT
ATAAGAGACAG-CCTACGGGNGGCWGCAG-3′; underlined
sequence indicates the target region primer) and 805R (5′-
GTCTCGTGGGCTCGG-AGATGTGTATAAGAGACAG-GACTA
CHVGGGTATCTAATCC-3′) targeting the V3 to V4 regions
of the 16S ribosomal RNA (rRNA) gene. The reaction
conditions were as follows: 3 minutes of initial denaturation
at 95°C, 25 cycles of 30-second denaturation at 95°C, 30-
second primer annealing at 55°C, 30-second elongation at
72°C, and a final extension at 72°C for 5 minutes. Secondary
amplification was performed using the i5 forward primer
(5′-AATGATACGGCGACCACCGAGATCTACAC-XXXXXXXX-
TCGTCGGCAGCGTC-3′; X indicates the barcode region) and
i7 reverse primer (5′-CAAGCAGAAGACGGCATACGAGAT-
XXXXXXXX-GTCTCGTGGGCTCGG-3′) for attaching the
Illumina NexTera barcode. The secondary amplification
conditions were identical to those of the first amplification
except that the number of amplification cycles was set
to eight. The amplified products were confirmed using
gel electrophoresis on 1.0% agarose gel and visualized
using a Gel Doc system (BioRad, Hercules, CA, USA).
CleanPCR (CleanNA) was used for purifying the amplified
products. The same concentrations of purified product were
pooled and short fragments were removed using CleanPCR
(nontarget product). The product size and quality were
evaluated on a Bioanalyzer 2100 (Agilent, Palo Alto, CA,
USA) using a DNA 7500 chip. Mixed amplicons were pooled
and sequenced using an Illumina MiSeq Sequencing system
(Illumina, Inc., San Diego, CA, USA) at ChunLab, Inc. (Seoul,
Korea) according to the manufacturer’s instruction. Raw read
processing began with quality checking and filtering of low-
quality (<Q25) reads by Trimmomatic 0.32.31 Paired-end
sequence data were merged using PANDAseq after passing
the quality control.32 Then, the primers were trimmed
with ChunLab’s in-house program at a similarity cutoff
of 0.8. HMMER’s hmmsearch program was used to detect
nonspecific amplicons that do not encode 16S rRNA.33 The
sequence was denoised using DUDE-Seq and nonredun-
dant reads extracted with UCLUST-clustering.34,35 After the
EzBioCloud database was searched for taxonomic assign-
ment using USEARCH (8.1.1861_i86linux32), more precise
pairwise alignment was performed.35,36 To detect chimeras
in reads with <97% best hit similarity rates, UCHIME and
the nonchimeric 16S rRNA database from EzBioCloud
were used.37 Reads that were not identified to the species
level (with <97% similarity) in the EzBioCloud database
were compiled and UCLUST was used for de novo clus-
tering to generate additional Operational Taxonomic Unit
(OTUs).35 OTUs with single reads were omitted from further
analysis.
Sequence Analysis
We clustered the sequences and grouped them as OTUs.
BIOiPLUG software (ChunLab) was used to summarize the
OTU data and to calculate the microbial alpha and beta
diversity, and a linear discriminant analysis (LDA) of the
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FIGURE 1. Clinical manifestations in the mouse cornea. (A) Representative images of mouse cornea before and after the PBS and IRT5
treatment. Lissamine Green B was used to visualize the wounded areas of the mouse corneas. (B) The ocular staining score of the IRT5-
treated group (n = 14, 28 eyes) was significantly lower than that of the PBS-treated group (n = 12, 24 eyes). (C) Tear secretion in the
IRT5-treated group was significantly higher than that of the PBS-treated group. ****P < 0.0001 (data presented as box-and-whisker plot with
median).
effect size (LEfSe) was determined for each sample. Alpha
diversity is an analysis of the diversity within a commu-
nity, including the Chao1 index, Shannon index, and phylo-
genetic diversity index. The microbial beta diversity was
compared using Bray-Curtis and UniFrac. An LEfSe and the
Kruskal-Wallis test were used to estimate the effect of abun-
dance in each sample on the effect of differences and to
identify the bacterial taxa that showed significant differ-
ences in their demarcation. Only those taxa that showed
a P value <0.05 and a log LDA score ≥2 were ultimately
considered.38 The multiple test corrections were based on
the FDR. An FDR of 0.05 was used as a statistically significant
cutoff.
Statistical Analyses
GraphPad Prism software, Version 7.04 (GraphPad Prism,
Inc., San Diego, CA, USA) was used. For comparing the
two groups, independent t-tests or nonparametric Mann-
Whitney U tests were used. To compare changes over time,
Wilcoxon matched-pairs signed rank tests were used. The
Shapiro-Wilk test was used for testing the normality of the
data. Differences were considered statistically significant at
P < 0.05.
RESULTS
IRT5 Treatment Improves Clinical Manifestations
in an Autoimmune Dry Eye Model
Compared to the pretreatment group (P < 0.0001, Wilcoxon
matched-pairs signed rank test) and the PBS treatment group
(P < 0.0001, Mann-Whitney U test), 3 weeks of treatment
with IRT5 significantly decreased the ocular staining score
(Figs. 1A, 1B). Tear secretion also increased after IRT5 treat-
ment compared with the pretreatment group (P < 0.0001,
Wilcoxon matched-pairs signed rank test) or PBS treatment
group (P < 0.0001, Mann-Whitney U test, Fig. 1C).
IRT5 Probiotics Change Immunomodulatory or
Ionic Transport-Related Protein Expression in the
Extraorbital Glands
Quantitative proteome analysis identified a total of 5379
proteins in the extraorbital glands with a FDR of less than 1%
at peptide spectrum match levels (Supplementary Table S1).
Among the identified proteins, 202 proteins were selected
as DEPs (changes in expression ≥1.15-fold of the reporter
ion intensity using Student’s t-test; P < 0.05) (Fig. 2A,
Supplementary Table S2). To gain insight into the func-
tional roles of DEPs in the effects of ITR5 treatment, a
comparison of the gene ontology (GO) of the biological
processes (BPs) of the DEPs was performed. A heatmap of
GOBP enrichment analysis showed significantly represented
GOBP terms (P < 0.05) for DEPs in the IRT5-treated group
compared with the PBS-treated group. Proteins related
to immune system process and defense response were
significantly downregulated and proteins associated with
actin cytoskeleton organization, cell adhesion, and prote-
olysis were significantly upregulated (Fig. 2B). To under-
stand the changes in the maps of the cellular networks in
the lacrimal glands after IRT5 treatment, we constructed
network models using the DEPs from the lacrimal glands.
We grouped the network proteins into eight modules,
including protein transport, exocytosis/endocytosis, lipid
metabolic process, proteolysis, immune system process, cell
cycle, mitochondria electron transfer, and cell adhesion
based on the GO biological processes and KEGG pathways
(Fig. 3).
Among these DEPs, Table 1 lists the proteins that
exhibited high betweenness centrality (the top 10% of
protein-protein interactions). The proteins that possessed
the high betweenness centrality (>0.5, the top 7% of
protein-protein interactions in decreasing order) were mito-
chondrial cytochrome c oxidase subunit 7C (Cox7c), zyxin
(Zyx), charged multivesicular body protein 4c (Chmp4c),
peroxisome assembly factor 2 (Pex2), paraplegin (Spg7),
ubiquitin-conjugating enzyme E2 D3 (Ube2d3), sedoheptu-
lokinase (Shpk), receptor-type tyrosine-protein phosphatase
C (PTPRC), and Golgi SNAP receptor complex member 2
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FIGURE 2. Volcano plot of total protein identified in the extraorbital lacrimal glands after the PBS (n = 5) and IRT5 (n = 5)
treatment and gene ontology analysis of 202 DEPs. (A) Volcano plot displaying all proteins that were identified by at least two
unique peptides. (B) The heat map of the GOBP enrichment analysis showed significantly represented GOBP terms (P < 0.05)
in the IRT5-treated group (only biological processes that satisfy P < 0.05 were included). Proteins associated with immune system
process were significantly downregulated and proteins related to actin cytoskeleton organization, cell adhesion, and proteolysis were
upregulated.
FIGURE 3. Protein network showing the proteomic changes after the PBS (n = 5) and IRT5 (n = 5) treatment. Protein interaction was
schematized as a network using STRING and the Cytoscape program.
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TABLE 1. Differentially Expressed Proteins that Have High Betweenness Centrality
Gene Protein Betweenness
Name Name Centrality Fold Change P Value
Cox7c Cytochrome c oxidase subunit 7C, mitochondrial 1.000 0.870 0.001
Zyx Zyxin 1.000 1.269 0.022
Chmp4c Charged multivesicular body protein 4c 0.667 1.261 0.012
Pex6 Peroxisome assembly factor 2 0.667 1.229 0.016
Spg7 Paraplegin 0.667 1.544 0.049
Ube2d3 Ubiquitin-conjugating enzyme E2 D3 0.667 0.813 0.045
Shpk Sedoheptulokinase 0.650 1.197 0.041
Ptprc Receptor-type tyrosine-protein phosphatase C 0.521 0.757 0.000
Gosr2 Golgi SNAP receptor complex member 2 0.500 0.855 0.003
Psmb8 Proteasome subunit beta type-8 0.254 0.805 0.008
Rac2 Ras-related C3 botulinum toxin substrate 2 0.221 0.728 0.005
H2-K1 H-2 class I histocompatibility antigen, K-B alpha chain 0.215 0.772 0.000
Icam1 Intercellular adhesion molecule 1 0.171 0.835 0.025
Agps Alkyldihydroxyacetonephosphate synthase, peroxisomal 0.150 0.858 0.009
D2hgdh D-2-hydroxyglutarate dehydrogenase, mitochondrial 0.150 0.845 0.047
*> 0.05 P value, >1.2- or <0.83-fold change, >0.1 betweenness centrality cutoff was applied.
TABLE 2. DEPs Related to Dry Eye, Sjögren Syndrome, or Autoimmune Disease Through Immune Modulation
Biological Process Protein Name Gene Name Fold Changes
Immune response Receptor-type tyrosine-protein phosphatase C Ptprc 0.757
High mobility group protein B2 Hmgb2 0.774
Proteasome subunit beta type-8 Psmb8 0.805
H-2 class II histocompatibility antigen, A-B alpha chain H2-Aa 0.666
H-2 class I histocompatibility antigen, K-B alpha chain H2-K1 0.772
Proteasome activator complex subunit 1 Psme1 0.853
Antigen peptide transporter 1 Tap1 0.765
Antigen peptide transporter 2 Tap2 0.815
Proteasome subunit beta type 9 Psmb9 0.770
Cell adhesion Intercellular adhesion molecule 1 Icam1 0.835
*> 0.05 P value, >1.2- or <0.83-fold change was applied for enriching the DEPs.
(Gosr2). Among these, Shpk and Ptprc are enriched in
immune system process with high betweenness centrality in
this network model. Additionally, Pex6, Gosr2, protein trans-
port protein Sec16B (Sec16b), antigen peptide transporter
2 (TAP2), and antigen peptide transporter 1 (TAP1) are
grouped in protein transport forming a close network with
immune system process within the protein-protein network
model (Fig. 3).
Among the DEPs, proteins that have been reported to
be associated with dry eye syndrome, Sjögren syndrome,
or autoimmune disease through modulating immunity are
shown in Table 2. Ptprc, which plays an important role in
T-cell activation and B-cell proliferation in the MRL/MpJ-
lpr mouse model, was downregulated and clustered in
immune system process after IRT5 treatment. High mobil-
ity group protein B2 (Hmgb2), which is reportedly highly
expressed in Sjögren syndrome, was downregulated after
IRT5 treatment. These proteins are mostly involved in
immune system process and may be significant in restor-
ing the functioning of the lacrimal gland after IRT5
treatment. Although its relationship with dry eye is not
clear, Cox 7c, one of the terminal oxidases of mitochon-
drial electron transfer, was also downregulated after IRT5
treatment.
Treatment with IRT5 Probiotics Changes Gut
Microbiome Composition
To promote the survival of IRT5 probiotics in the gut, oral
antibiotics were applied for 5 days prior to treatment in
26 mice in both the PBS (n = 12) and IRT5 (n = 14)
groups. Of the 26 mice, 3 mice from the PBS group and
4 from the IRT5 group underwent gut microbiome analy-
sis. The average taxonomic composition changed in both
groups (Fig. 4A, Supplementary Table S3). The Firmicutes
to Bacteroidetes ratio was not significantly different between
the two groups, and there was also no difference between
pre- and posttreatment samples (Fig. 4B). There were no
significant differences in the alpha diversity analyzed using
the Chao1 index, Shannon index, or phylogenetic diversity
index (Fig. 4C). The separation between the IRT5 and PBS
groups was observed using a Bray-Curtis principal coordi-
nate analysis (Fig. 4D).
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FIGURE 4. Gut microbiome changes after the PBS (n = 3) and IRT5 (n = 4) treatment with antibiotic pretreatment. (A) Average taxonomic
composition at the family level before and after the PBS and IRT5 treatment. (B) The Firmicutes to Bacteroidetes ratio was not significantly
different between the two groups. (C) Alpha diversity analyzed using the Chao1 index, Shannon index, and phylogenetic diversity index.
No significant differences were observed between before and after the PBS and IRT5 treatments. (D) Scatterplot showing the first principal
coordinate (PC) versus the second PC using Bray-Curtis and UniFrac analysis. Percentages shown are the percentages of variation explained
by the components.
LEfSe analysis and Kruskal-Wallis tests were performed
to compare the differences in gut microbiota pre- and
posttreatment and between the IRT5 and PBS groups. In
the IRT5-treated group, the taxonomic relative abundance
of 33 different OTUs, including a Lactobacillus helveti-
cus group, Lactobacillus hamsteri, a L. reuteri group, a L.
casei group, a Lactobacillus brantae group, a Lactobacillus
amylovorous group, Akkermansiamuciniphila, an Aerococ-
cusviridans group, B. bifidum, and a Streptococcus salivar-
ius group, was significantly higher than in the PBS-treated
group. In contrast, the relative abundance of 53 OTUs,
including an Escherichia coli group, was significantly lower
in the IRT5-treated group than in the PBS-treated group
(Supplementary Table S4).
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FIGURE 5. Effect of the IRT5 treatment without antibiotics pretreatment in an autoimmune dry eye mouse model. (A) Ocular staining score
was significantly lower in the IRT5-treated group (n = 5, 10 eyes) than in the PBS-treated group (n = 4, 8 eyes). However, the phenol red
thread test results were not significantly changed after IRT5 treatment. (B) In the conjunctiva and cornea of the IRT5-treated group, IL-1β
was significantly lower (P = 0.0434) and IL-10 was significantly higher (P = 0.0343) than in the PBS-treated group. (C) Average taxonomic
composition at the family level before and after the PBS (n = 4) and IRT5 (n = 5) treatment is shown. (D) The Firmicutes to Bacteroidetes
ratio and alpha diversity analyzed using the Chao1 index were not significantly different between the two groups. (E) Compared to the PBS-
treated group, Lactobacillus intestinalis was lower, and the Lactobacillus helveticus group, Lactobacillus hamsteri, and the Staphylococcus
saprophyticus group were higher in the IRT5-treated group.
IRT5 Probiotics Treatment without Antibiotic
Pretreatment Also Improves Autoimmune Dry Eye
and Modifies Gut Microbiome Composition
To rule out the effect of antibiotics, we conducted an addi-
tional experiment administering IRT5 probiotics or PBS
without pretreatment with antibiotics. After IRT5 treatment
without the antibiotic pretreatment, the ocular staining
scores significantly decreased compared with the pretreat-
ment group (P = 0.0042, Wilcoxon matched-pairs signed
rank test) and the PBS treatment group (P = 0.0011, Mann-
Whitney U test). However, tear secretion was not significantly
different in the IRT5-treated group when compared with the
PBS-treated group (P = 0.6334, Mann-Whitney U test) or the
pretreatment group (P = 0.5566, Wilcoxon matched-pairs
signed rank test) (Fig. 5A).
The IL-10 was significantly higher (P = 0.0343, Mann-
Whitney U test) and the IL-1β significantly lower (P= 0.0434,
Mann-Whitney U test) in the conjunctiva and cornea of the
IRT5-treated group (Fig. 5B).
The averaged taxonomic composition changed in both
groups (Fig. 5C). Neither the Firmicutes to Bacteroidetes
ratio nor alpha diversity showed any significant differences
between the IRT5-treated group and either the pretreat-
ment group or the PBS-treated group (Fig. 5D). Includ-
ing the L. helveticus group, L. hamsteri, and the Staphy-
lococcus saprophyticus group, the proportion of 12 OTUs
was increased in the IRT5-treated group compared with the
PBS treated group. In contrast, 15 OTUs, including Lacto-
bacillus intestinalis, were decreased in the IRT5-treated
group compared with the PBS-treated group (Fig. 5E,
Table 3).
IRT5 Treatment Downregulates Antigen
Presentation by the Immune Cells
Notably, the IRT5 and PBS treatment showed more differ-
ences in the CD11c+ and CD11b+ cells of the spleen than in
the CD3+ cells of the lymph node, and the splenic CD11c+
cells showed the largest difference between the PBS treat-
ment group and the IRT5 treatment group (Supplementary
Fig. S1). A total of 574 DEPs were identified in the spleen
CD11c+ cells. Proteins associated with antigen presentation
were significantly decreased in the spleen CD11c+ cells of
the IRT5-treated group (Table 4).
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TABLE 3. Differences in Abundance of Bacterial Communities as Assessed by LEfSe
Taxon Name Post PBS Post IRT LDA Effect Size q Value
Increased
PAC001071_s 1.40115 2.54230 3.75640 0.01452
PAC001112_s 1.14062 2.00330 3.63493 0.01453
PAC001118_s 0.00739 0.69573 3.53691 0.02864
Lactobacillus helveticus group 0.00000 0.21799 3.03857 0.01054
PAC002441_s 0.25844 0.38583 2.80774 0.01466
PAC001244_s 0.00341 0.12922 2.80012 0.01401
Staphylococcus saprophyticus group 0.00213 0.06748 2.51554 0.02861
EU511112_s 0.00487 0.05132 2.37711 0.02846
PAC001550_s 0.01650 0.05921 2.34357 0.01461
PAC001370_s 0.00000 0.00775 2.12212 0.01056
Lactobacillus hamsteri 0.00604 0.02909 2.10369 0.02840
PAC001549_s 0.01097 0.02841 2.01551 0.01459
Decreased
Lactobacillus intestinalis 10.72607 4.84257 4.46862 0.02843
PAC001128_s 0.58433 0.33275 3.10076 0.02849
PAC001121_s group 0.25399 0.01503 3.07787 0.01400
PAC001554_s 0.22915 0.08702 2.85228 0.01462
PAC001560_s 0.14342 0.01524 2.80823 0.01464
PAC002039_s 0.13548 0.00990 2.79886 0.01404
PAC002419_s 0.12160 0.05311 2.53967 0.02855
PAC001586_s 0.05931 0.00502 2.43771 0.02562
PAC001235_s 0.08000 0.02974 2.41812 0.01456
PAC002314_s 0.04626 0.00175 2.35018 0.02568
PAC001588_s 0.05335 0.01130 2.33173 0.02565
PAC001402_s 0.05175 0.01300 2.29307 0.01458
PAC001543_s 0.03263 0.00800 2.12408 0.05199
PAC001536_s 0.02481 0.00000 2.10187 0.03048
PAC001772_s 0.02204 0.00468 2.07747 0.01403
TABLE 4. Differentially Expressed Proteins Associated with Antigen Presentation in the Spleen CD11c+ Cells








(IRT5/PBS) P Value P Value
Class II histocompatibility antigen, M beta 1 chain (H2-M
beta 1 chain)
H2-DMb1 0.468 0.000
H-2 class I histocompatibility antigen, D-37 alpha chain H2-T23 0.576 0.026
Immunoglobulin J chain Jchain 0.488 0.281 0.001 0.006
Ig alpha chain C region IGHA1 0.507 0.003
Ig gamma-2B chain C region Igh-3 0.469 0.000
DISCUSSION
The present study indicates that the application of IRT5
probiotics changes the protein expression associated with
immunomodulation in the extraorbital lacrimal gland, result-
ing in the improvement of dry eye signs. This is interesting as
it is the first experimental study to report that the proteome
of the lacrimal gland can be altered by modulating the gut
microbiome.
IL-1β was significantly lower and IL-10 significantly
higher in the conjunctiva and cornea of the IRT5-treated
group than in those of the PBS-treated group. Similarly,
there was a tendency toward an increase of IL-10, an anti-
inflammatory cytokine, and decreases of IL-6 and IL-1β in
the extraorbital lacrimal glands of the IRT5-treated group,
despite the fact that the trend was not significant due to
the small sample size (Supplementary Fig. S2). These find-
ings are in line with our previous report that the inflamma-
tion foci score of the extraorbital lacrimal gland was signif-
icantly lower in the IRT5 group than in the PBS group.25
Changes in the lacrimal glands can affect the ocular surface,
possibly through tears containing anti- and proinflamma-
tory cytokines, growth factors, and other proteins. Although
we did not evaluate the tear directly, our results suggest
that changes in the lacrimal gland may affect the ocular
surface.39,40
In particular, Psmb9, PTPRC, and TAP2, which are known
to be upregulated in Sjögren syndrome,41–46 were down-
regulated in IRT5-treated mice. Psmb8 and Psmb9 acti-
vate NF-κ B in B cells and process the numerous MHC
class I restricted T-cell epitopes.47 PTPRC modulates signal-
ing mediated by the T-cell receptor and activates B-cell
antigen receptor signaling, which modulates susceptibil-
ity to autoimmune diseases.48 TAP2 is involved in the
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transportation of antigens from the cytoplasm to the endo-
plasmic reticulum for association with MHC class I epitopes,
and TAP2 polymorphism has been associated with anky-
losing spondylitis.49 Psmb8 and PTPRC also showed strong
centralities within immune system process and could be
regarded as key molecules in the anti-inflammatory role
of IRT5 treatment. This finding corresponds well with the
results of a previous meta-analysis showing these proteins to
be key contributors to Sjögren syndrome in humans. There-
fore, we reasoned that IRT5 treatment ameliorates dry eye
signs by reducing the level of these proteins and their related
biological processes. Although its association with Sjögren
syndrome is not clear, the expression of intracellular adhe-
sion molecule 1 was also attenuated. HMGB2, as a prob-
able factor causing or aggravating Sjögren syndrome,50–54
showed moderate centrality between leukocyte-cell adhe-
sion and the phagocytosis network, and its expression
decreased with IRT5 treatment. Cox7c, which was down-
regulated, reduces electron transfer and decreases the mito-
chondrial H+ gradient. Therefore, Cox7c downregulation
may reduce adenosine triphosphate (ATP) production and
decrease activation of P2 purinergic receptors, which may
contribute to inflammatory processes.55
Among the upregulated DEPs was Chmp4c, one of the
components of transport complex III. Chmp4c sorts endo-
somal cargo proteins into multivesicular bodies (MVBs) and
is involved in MVB formation. Chmp4c showed a higher rate
of expression when treated with IRT5, which may result in
the formation of MVBs that may, in turn, affect degrada-
tion processes. Pex6, a member of the AAA (ATPases associ-
ated with diverse cellular activities) family of ATPases, also
helps with protein import into peroxisomes. Peroxisomes
have two functions, diverse reactions in the lipid metabolism
and defense systems for scavenging peroxides and reactive
oxygen species.56 Upregulation of Pex6 may reduce oxida-
tive stress by promoting the import of peroxisomal protein.
In addition, Ube2d3, encoding a member of the E2
ligase family, was downregulated, although genes encod-
ing the other DEPs associated with proteolysis and degrada-
tion were upregulated after IRT5 treatment. The connection
between proteolysis and dry eye is not clear. Given that the
ubiquitin proteasome pathway is responsible for generating
the precise C termini of MHC-presented peptides, proteolytic
changes may be associated with immune response.57
Gut dysbiosis plays an important role in autoimmune
disease. Sjögren syndrome also shows reduced diversity
in the gut microbiota.11 A recent clinical study reported
that administration of Bifidobacterium may attenuate dry
eye syndrome.21 In agreement with this observation, our
previous25 and current preclinical studies both showed that
changes in the gut microbiome after IRT5 treatment were
associated with improvements in the clinical signs of autoim-
mune dry eye disease.
Interestingly, the L. helveticus group and L. hamsteri
were higher in the IRT5 group than in the PBS group,
regardless of antibiotic pretreatment. The R0052 strain of
L. helveticus is a component of Lacidofil (Rosell Institute,
Montreal, Canada) and has been used as a probiotic since
1995.58 It has been reported that it inhibits the adhesion
of bacteria and modulates immune function by downregu-
lating proinflammatory cytokines.59–61 Additionally, the NS8
strain of L. helveticus has also been reported to exhibit
immunomodulatory properties by inducing higher levels
of IL-10.62,63 Although no clinical studies have reported
that Lactobacillus intake increases IL-10 expression on the
ocular surface, an increase of serum IL-10 with an immuno-
suppressive effect was shown after Lactobacillus intake in
atopic dermatitis.64 Consistent with previous reports, IL-10
on the ocular surface was increased in the IRT5-treated
group, suggesting that the immunomodulatory effect might
be related to L. helveticus. Therefore, we believe that probi-
otics may alter the gut microbiome to show systemic anti-
inflammatory effects that could reach the ocular mucosal
surface as well as other targets of autoimmune disease.
However, not many studies on L. hamsteri have been
published. Therefore, the immunomodulating function of
L. hamsteri needs to be further evaluated. Interestingly, three
(the L.s reuteri group, the L. casei group, and B. bifidum) of
the five strains constituting IRT5 were increased in the IRT5-
treated group compared with the PBS-treated group only
when antibiotic pretreatment was provided. Correspond-
ingly, tear secretion increased in the IRT5-treated group only
when antibiotic pretreatment was performed. These results
suggest that pretreatment with antibiotics promotes IRT5
establishment and maximizes the therapeutic effects without
severely diminishing microbial diversity. Suez et al.65 also
reported that antibiotic treatment partially alleviated resis-
tance to probiotic species and mildly enhanced probiotic
colonization.
However, there is controversy about pretreatment with
antibiotics before taking probiotics. Manichanh et al.66
reported a twofold decrease in microbial load after admin-
istration of imipenem and vancomycin for 3 days. They
also reported a significant decrease of Bacteroidetes and an
increase of Firmicutes. Although not statistically significant,
the Firmicutes to Bacteroidetes ratio in our study increased
more than 10-fold in both the PBS- and IRT5-treated groups
after antibiotic pretreatment, while the ratio remained the
same without the antibiotic pretreatment. In addition, antibi-
otic intake changed the taxonomic composition but did not
reduce microbial diversity. Previous studies have reported a
wide range of losses of alpha diversity after antibiotic expo-
sure, ranging from 10% to 80%.67–69 This might be due to
differences in the type of antibiotics used or the vulnerability
of the host. Since it is known that changes in the gut micro-
biome caused by antibiotics increase the risk of diabetes and
allergies, further research on the immune system changes
caused by antibiotics should be conducted.70
It is well known that the gut microbiome is involved in
the host immune system, but the mechanism is unclear.71
We could not directly correlate proteomic changes in the
lacrimal gland with compositional changes in the gut micro-
biome. Given the previous report that probiotics cause
a large change in intestinal transcription without signifi-
cantly changing the composition of the microbiome,72 it
can be inferred that the changes in the microbiome after
IRT5 administration influenced the lacrimal protein changes
in this study. Using an additional mechanistic study, we
revealed that the CD11c+ cells of the spleen showed larger
proteomic changes than the CD3+ cells of the lymph nodes.
We found that the proteins related to the antigen presen-
tation pathway were significantly decreased in the IRT5-
treated group. This is consistent with previous reports that
the gut microbiome affects intestinal dendritic cell function-
ing and impacts immune homeostasis.73 To support these
findings, we retrospectively reanalyzed flow cytometry data
from the previous experiments.25 The proportion of MHCIIhi
cells in the cervical lymph node was also lower in the IRT5-
treated group (n = 10, 24.01 ± 3.69) than in the PBS-treated
group (n = 10, 28.58 ± 2.22) (P = 0.0052, Mann-Whitney
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FIGURE 6. Changes in the gut microbiome after IRT5 administration is suggested to contribute to the immune modulation of the eye via the
downregulation of the antigen presentation process in the spleen. Changes in metabolites caused by the gut microbiome and transmitted to
the eye through the bloodstream can also be hypothesized as a plausible mechanism.
U test) (Supplementary Fig. S3). From these results, it can
be deduced that the downregulation of antigen presenta-
tion is one of the mechanisms of the immunomodulation
caused by the administration of IRT5 (Fig. 6). Another spec-
ulation is that short-chain fatty acid or tryptophan deriva-
tives, which are known to affect neuroinflammation in the
central nervous system, may also contribute to the immune
modulation of the eye.74 Further studies are warranted to
identify the metabolites that affect the microbiome-gut-eye
axis.
Our study has some limitations. First, the analysis
method, which targeted the V3 to V4 regions of the 16S
rRNA gene, could not identify the exact strain of the micro-
biome. As it is known that actions can vary depending on
the type of strain even within one species, whole-genome
sequencing is needed. Similarly, the current study is based
on OTUs with a cutoff value of 97%. Even if the organisms
share more than 97% of the entire 16S rRNA gene sequence,
they may or may not represent the same species.75,76 Second,
the number of animals used in the experiment was small due
to difficulties in breeding them. Third, even if mice are bred
under the same food and environmental conditions, there
are already microbiome variations between the mice before
the experiment. Only male NOD.B10.H2b mice were used in
this experiment because females tend to develop sialadeni-
tis instead of dacryoadenitis.77 This sex restriction limited
co-housing before the experiments because males fight to
the death when co-housed. Additional pretreatment, such
as fecal microbiota transplantation, should be considered in
further experiments. Fourth, we could not invasively obtain
samples directly from the gut but instead collected noninva-
sive fecal samples. Given that the microbiome composition
is different in each part of the intestinal tract, the taxonomic
composition measured in the feces can be different.78,79
Therefore, using the fecal microbiome alone is limited in
determining the effects of IRT5 on the whole microbiome of
the host.
In this study, we investigated changes in the gut micro-
bial community and the proteome of the lacrimal gland after
IRT5 treatment in an animal model of Sjögren syndrome.Our
findings can be summarized as follows. First, ocular inflam-
mation and tear secretion improved after IRT5 treatment.
Second, proteins in defense response and immune system
process were downregulated in the extraorbital lacrimal
gland after IRT5 treatment. Third, IRT5 treatment induced
changes in the composition of several OTUs, including the
L. helveticus group and L. hamsteri. Our observations may
be beneficial in understanding the pathophysiology of the
gut-microbiota-eye axis in dry eye disease.
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